Position in GILD
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$393,170
-$8,494 QoQ
Shares Held
3,112
+8.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#1,503
of 2,266 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026VERUS CAPITAL PARTNERS, LLC holds $19,240,412 across 9 Drug Manufacturers - General names. GILD ranks #7 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
47,929 | $12,060,853 | |
| 2 | JNJ |
Johnson & Johnson
|
7,570 | $1,922,552 | |
| 3 | LLY |
ELI LILLY & Co
|
1,346 | $1,614,432 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
17,858 | $1,028,977 | |
| 5 | MRK |
Merck & Co., Inc.
|
7,818 | $1,004,613 | |
| 6 | AMGN |
Amgen Inc
|
1,263 | $457,357 | |
| 7 | GILD |
Gilead Sciences, Inc.
This page
|
3,112 | $393,170 | |
| 8 | PFE |
Pfizer Inc
|
15,911 | $383,136 |
All Filings in GILD
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $393,170 | 3,112 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $401,664 | 2,882 | Shares | Sole | 2026-05-22 | |
| 2025-12-31 | $442,354 | 3,604 | Shares | Sole | 2026-02-11 | |
| 2025-03-31 | $230,262 | 2,055 | Shares | Sole | 2025-05-13 | |
| 2022-12-31 | $235,829 | 2,747 | Shares | Sole | 2023-02-14 | |
| 2020-03-31 | $497,527 | 6,655 | Shares | Sole | 2020-05-26 | |
| No filing history on record for this holder in this stock. | ||||||